First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial
| Autor: | M, Kaufmann, N, Maass, S D, Costa, A, Schneeweiss, S, Loibl, M W, Sütterlin, I, Schrader, B, Gerber, W, Bauer, W, Wiest, O, Tomé, A, Distelrath, V, Hagen, A, Kleine-Tebbe, E, Ruckhaeberle, K, Mehta, G, von Minckwitz, C, Karg |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Breast Neoplasms Deoxycytidine Gastroenterology Disease-Free Survival Breast Neoplasms Male Metastasis Capecitabine Breast cancer Internal medicine medicine Humans Prospective Studies Neoplasm Metastasis Aged Aged 80 and over Chemotherapy business.industry Cancer Middle Aged medicine.disease Metastatic breast cancer Surgery Oncology Disease Progression Quality of Life Female Fluorouracil Breast disease medicine.symptom business medicine.drug |
| Zdroj: | European Journal of Cancer. 46:3184-3191 |
| ISSN: | 0959-8049 |
| Popis: | To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer.In this prospective phase II trial, patients with HER2-negative metastatic breast cancer received first-line capecitabine 2000 mg/m(2) on days 1-14 every 3 weeks. The primary aim was to exclude a time to progression (TTP)6 months. Secondary end-points were overall response rate, overall survival (OS), toxicity and quality of life.Median age of the 161 included patients was 65 years. Median TTP and OS were 7.3 months [95% (confidence interval) CI: 6.2-8.4] and 17.1 months (95% CI: 14.0-20.3), respectively. An overall response rate of 26.1%, including 13 complete remissions was observed. Patients developing grade I-III hand-foot syndrome had a significantly longer TTP and OS and patients65 years also achieved a significantly longer TTP. Haematological grade I-IV toxicities were leucopenia (64.0%), anaemia (50.9%) and thrombocytopenia (28.0%). Relevant non-haematological toxicities were hand-food-syndrome (37.3%), fatigue (34.2%), nausea (29.8%) and diarrhoea (20.5%). Quality of life assessment revealed an improved emotional function, but worsening of nausea and vomiting from cycle 1-10.Capecitabine at a dose of 2000 mg/m(2) is active and safe as first-line treatment of patients with metastatic breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect